News & Updates

Show Multimedia Only

Low vision-threatening DR incidence contrasts with high progression rate among Asians

07 Jul 2026 by

The overall development of vision-threatening diabetic retinopathy (DR) among Asians with diabetes is low, although the incidence of progression to vision-threatening disease for those who already have DR is high, according to local research.

Low vision-threatening DR incidence contrasts with high progression rate among Asians

07 Jul 2026

Comorbidities delay RT in patients with brain tumours

07 Jul 2026

Patients with malignant brain tumours and several comorbidities tend to have delayed radiotherapy (RT), reveals a study.

Comorbidities delay RT in patients with brain tumours

07 Jul 2026

Efgartigimod improves platelet response in primary ITP

07 Jul 2026 by

The use of efgartigimod in adult patients with primary immune thrombocytopenia (ITP) results in higher platelet response with no increase in serious adverse events (AEs), reports a meta-analysis of phase III randomized controlled trials (RCTs).

Efgartigimod improves platelet response in primary ITP

07 Jul 2026

MELD best predictor of outcomes in alcohol-related liver disease: study

07 Jul 2026

A recent study describes the natural history of alcohol-associated liver disease (ALD) and the risks of outcomes based on the model for end-stage liver disease (MELD) score across the ALD spectrum.

MELD best predictor of outcomes in alcohol-related liver disease: study

07 Jul 2026

Pooled KARDIA data show effective BP control with add-on zilebesiran

07 Jul 2026 by

A pooled analysis of data from the phase II KARDIA 2 and 3 studies shows the blood pressure (BP)-lowering potential of zilebesiran, an investigational, long-acting RNA interference therapeutic, when added to a renin–angiotensin–aldosterone system inhibitor (RAASi) in patients with hypertension (HTN).

Pooled KARDIA data show effective BP control with add-on zilebesiran

07 Jul 2026

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

07 Jul 2026

Among patients with viral hepatitis-related cirrhosis who sustained non-bleeding decompensating events, the use of non-selective beta blockers is associated with lower mortality, as shown in a study.

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

07 Jul 2026

Original New Drug Application Approvals by US FDA (1-15 June 2026)

07 Jul 2026

New drug applications approved by US FDA as of 1-15 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 June 2026)

07 Jul 2026

Inhaled nitrous oxide provides efficacious analgesia for outpatient hysteroscopic procedures

06 Jul 2026

The use of inhaled nitrous oxide during outpatient operative hysteroscopy helps reduce intraprocedural pain and promote successful completion of procedures, resulting in increased patient satisfaction, according to a study.

Inhaled nitrous oxide provides efficacious analgesia for outpatient hysteroscopic procedures

06 Jul 2026

Dual immune checkpoint blockade delivers encouraging survival benefit in LACC

06 Jul 2026 by

Neoadjuvant nivolumab plus ipilimumab followed by chemoradiation and maintenance nivolumab yields high survival rates in locally advanced cervical cancer (LACC), according to final survival data from the phase II COLIBRI-1 trial.

Dual immune checkpoint blockade delivers encouraging survival benefit in LACC

06 Jul 2026

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

06 Jul 2026

In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

06 Jul 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Low vision-threatening DR incidence contrasts with high progression rate among Asians

Low vision-threatening DR incidence contrasts with high progression rate among Asians

Comorbidities delay RT in patients with brain tumours

Comorbidities delay RT in patients with brain tumours

Efgartigimod improves platelet response in primary ITP

Efgartigimod improves platelet response in primary ITP

MELD best predictor of outcomes in alcohol-related liver disease: study

MELD best predictor of outcomes in alcohol-related liver disease: study

Pooled KARDIA data show effective BP control with add-on zilebesiran

Pooled KARDIA data show effective BP control with add-on zilebesiran

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

Original New Drug Application Approvals by US FDA (1-15 June 2026)

Original New Drug Application Approvals by US FDA (1-15 June 2026)

Inhaled nitrous oxide provides efficacious analgesia for outpatient hysteroscopic procedures

Inhaled nitrous oxide provides efficacious analgesia for outpatient hysteroscopic procedures

Dual immune checkpoint blockade delivers encouraging survival benefit in LACC

Dual immune checkpoint blockade delivers encouraging survival benefit in LACC

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

Switching to entecavir reduces relapse, flare in HBeAg-negative patients